FDA grants Medivir’s MIV-711 Rare Pediatric Disease Designation for Osteogenesis Imperfecta

AI SummaryClose X

FDA granted Rare Pediatric Disease Designation (RPDD) to Medivir’s MIV-711 for Osteogenesis Imperfecta, reinforcing its Orphan Drug Designation and positioning the program ahead of a planned proof-of-concept study with secured funding; Medivir estimates a minimum market potential of USD 2.5 billion and MIV-711 could, upon approval, yield a transferable Priority Review Voucher worth USD 180–210 million (PRV program runs through 30 Sep 2029). Preclinical OI models showed significant dose-dependent improvements in bone strength and clinical osteoarthritis data support human activity, addressing an area with no approved disease-modifying therapy.

Disclaimer*

Companies

Medivir AB (0GP7)
UK 100

Latest directors dealings